Equities research analysts expect that OvaScience Inc (NASDAQ:OVAS) will post earnings per share (EPS) of ($0.46) for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for OvaScience’s earnings, with estimates ranging from ($0.57) to ($0.35). OvaScience reported earnings of ($0.80) per share in the same quarter last year, which would suggest a positive year over year growth rate of 42.5%. The business is scheduled to announce its next earnings results on Thursday, May 4th.
According to Zacks, analysts expect that OvaScience will report full year earnings of ($1.93) per share for the current year, with EPS estimates ranging from ($2.36) to ($1.37). For the next financial year, analysts expect that the firm will report earnings of ($1.55) per share, with EPS estimates ranging from ($1.87) to ($0.99). Zacks’ earnings per share averages are an average based on a survey of research analysts that that provide coverage for OvaScience.
OvaScience (NASDAQ:OVAS) last released its earnings results on Thursday, March 2nd. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.58) by $0.06. OvaScience had a negative return on equity of 62.66% and a negative net margin of 11,642.67%. The business had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.11 million. During the same quarter in the previous year, the firm posted ($0.76) EPS. The business’s revenue for the quarter was down 25.0% on a year-over-year basis.
Several research analysts have issued reports on OVAS shares. Zacks Investment Research upgraded shares of OvaScience from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a research report on Wednesday, March 8th. Oppenheimer Holdings Inc. restated a “hold” rating on shares of OvaScience in a research report on Sunday, December 25th. Finally, Credit Suisse Group AG restated an “underperform” rating and issued a $1.00 price target on shares of OvaScience in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $4.38.
OvaScience (NASDAQ:OVAS) traded down 1.39% during trading on Tuesday, reaching $1.42. The company’s stock had a trading volume of 388,849 shares. The firm has a 50 day moving average of $1.60 and a 200 day moving average of $2.80. OvaScience has a 52 week low of $1.30 and a 52 week high of $11.66. The stock’s market capitalization is $50.61 million.
Institutional investors have recently bought and sold shares of the company. Teachers Advisors LLC raised its position in OvaScience by 53.0% in the fourth quarter. Teachers Advisors LLC now owns 68,249 shares of the biotechnology company’s stock worth $104,000 after buying an additional 23,643 shares in the last quarter. Northern Capital Management LLC raised its position in OvaScience by 92.6% in the first quarter. Northern Capital Management LLC now owns 91,865 shares of the biotechnology company’s stock worth $172,000 after buying an additional 44,175 shares in the last quarter. Oppenheimer & Co. Inc. raised its position in OvaScience by 5.2% in the third quarter. Oppenheimer & Co. Inc. now owns 54,826 shares of the biotechnology company’s stock worth $393,000 after buying an additional 2,714 shares in the last quarter. Tudor Investment Corp Et Al raised its position in OvaScience by 1,055.6% in the fourth quarter. Tudor Investment Corp Et Al now owns 338,904 shares of the biotechnology company’s stock worth $519,000 after buying an additional 309,578 shares in the last quarter. Finally, Third Security LLC purchased a new position in OvaScience during the fourth quarter worth approximately $571,000. 79.61% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “-$0.46 Earnings Per Share Expected for OvaScience Inc (OVAS) This Quarter” was first posted by Markets Daily and is the property of of Markets Daily. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.themarketsdaily.com/2017/04/21/0-46-earnings-per-share-expected-for-ovascience-inc-ovas-this-quarter.html.
OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OvaScience Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience Inc and related companies with MarketBeat.com's FREE daily email newsletter.